Blood Test

The FDA has granted breakthrough device designation to Amadix’s PreveCol, a blood test for early detection of colorectal cancer, intended to screen adults aged 45 years or older without apparent symptoms, according to a company release.

The FDA has cleared BD MiniDraw, a capillary blood collection device developed by Babson Diagnostics and Becton, Dickinson and Company that allows clinicians to collect blood without a phlebotomist, according to a company press release.

The FDA has cleared a traumatic brain injury blood test for commercial availability, paving the way for its distribution to hospitals in the United States.

In those with traumatic brain injury, patterns of two blood-based biomarkers were similar between the sexes, with significantly higher concentrations of one in male patients compared with female patients, according to research from Nature.

Two widely available serum marker blood tests, galactomannan and 1,2-beta-D-glucan, may improve diagnostic sensitivity in cases of invasive fungal infections, according to a study.

Modern blood testing is the foundation of clinical screening and decision-making. Timely disease diagnosis, prevention and chronic care management depend on accurate diagnostic testing.

Researchers have developed a method to predict which individuals are at higher risk for lung cancer-related mortality.

C2N Diagnostics released the PrecivityAD2 blood test, which uses positron emission tomography scans and cerebrospinal fluid tests to assist in accurate diagnosis for those presenting with signs or symptoms of Alzheimer’s disease.

Quest Diagnostics has announced the availability of a blood-based test that assesses the risk of developing Alzheimer’s disease through amyloid-beta biomarkers.

A partnership between a clinical diagnostics company and a clinical manufacturing firm aims to support therapeutic development, clinical trials, reimbursement and routine clinical adoption for a range of neurodegenerative diseases.